Indacaterol

The First Once-daily Long-acting Beta2 Agonist for COPD

AvAlexandre Trifilieff

Inbunden, Engelska, 2013

Del i serien Milestones in Drug Therapy

1 098 kr

Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt över 249 kr.

Beskrivning

Here is a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled beta2 agonist for treating COPD. Covers design and pre-clinical pharmacology of the molecule, early clinical development, efficacy studies and more.

Produktinformation

Utgivningsdatum:2013-11-27
Mått:155 x 235 x 15 mm
Vikt:407 g
Format:Inbunden
Språk:Engelska
Serie:Milestones in Drug Therapy
Antal sidor:146
Upplaga:2014
Förlag:Springer Basel
ISBN:9783034807081

Utforska kategorier

Farmakologi inom Medicin
Lungmedicin inom Medicin

Innehållsförteckning

Current Pharmacotherapy for COPD.- The preclinical pharmacology of indacaterol.- The design of the indacaterol molecule.- The early clinical development of Indacaterol.- INHANCE: An adaptive confirmatory study with dose selection at interim.- Phase III clinical efficacy studies – lung function.- Phase III Clinical Efficacy of Indacaterol.- Patient-centered Outcomes.- The history and performance of the Breezhaler device.- What does the future hold for the therapy of COPD?